Aridis’ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDA’s Qualified Infectious Diseases Product (QIDP) Designation
12. Juli 2023 08:00 ET
|
Aridis Pharmaceuticals, Inc.
QIDP designation for Biologics provides FDA Priority Review status LOS GATOS, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company...
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
14. Oktober 2020 11:00 ET
|
RedHill Biopharma Ltd.
RHB-204 Phase 3 study in pulmonary NTM infections is planned to be initiated in the coming weeks--Orphan Drug Designation, along with RHB-204’s FDA QIDP priority designation, will extend U.S....
FDA Grants Qualified Infectious Disease Product Designation to Taksta(TM) Cempra's Fusidic Acid Antibiotic
18. September 2015 07:00 ET
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., Sept. 18, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Melinta Therapeutics Demonstrate Delafloxacin's Potent and Rapid Antimicrobial Activity against Neisseria Gonorrhoeae
08. September 2014 11:01 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced results from in vitro studies that highlight the
potential of delafloxacin, an
investigational fluoroquinolone,...
Melinta Therapeutics Highlighting Delafloxacin and ESKAPE Candidates in Twelve Presentations at 2014 ICAAC Meeting
04. September 2014 10:45 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that an additional three abstracts have been accepted as
late-breakers at the annual Interscience Conference...
Melinta Therapeutics Reports Top-Line Results Showing Equivalent Exposures after Oral and Intravenous Delafloxacin Administration
11. August 2014 12:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced top-line results of a Phase 1 clinical study that
demonstrated that the administration of single doses of...
Melinta Therapeutics' Phase 3 Study of I.V. and Oral Delafloxacin has Begun Enrolling Patients with Acute Bacterial Skin and Skin Structure Infections
05. Mai 2014 11:27 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, May 5, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced that patient enrollment has commenced in a Phase 3 trial
of oral and intravenous (I.V.) delafloxacin, a...
Melinta Therapeutics to Present at Needham & Company's Annual Healthcare Conference
03. April 2014 14:38 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, April 3, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced that Mary Szela, the Company's chief executive
officer, will be presenting a corporate update at Needham...
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
10. Februar 2014 07:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...
Melinta Therapeutics Initiates Phase 3 Registration Study of Delafloxacin in Individuals with Uncomplicated Gonorrhea
09. Januar 2014 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics
today announced the initiation of a Phase 3 trial of delafloxacin,
a novel investigational fluoroquinolone, for the...